AC Immune SA (ACIU) vs Amarin (AMRN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
AC Immune SA (ACIU) has outperformed Amarin (AMRN) over the past year, losing 28.4% versus a loss of 37.6%. Over five years, ACIU leads with a -58.4% price change compared with -88.4% for AMRN. AC Immune SA is the larger company by market cap ($253.5 million vs $251.4 million), about 1.0 times the size.
On valuation, AC Immune SA trades at a lower forward P/E (4.3x vs 12.1x for Amarin).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACIU | AMRN |
|---|---|---|
| Share price | $2.55 | $11.90 |
| Market cap | $253.54M | $251.36M |
| 1-day change | -0.78% | -1.00% |
| YTD return | -18.15% | -13.90% |
| 1-year return | -28.41% | -37.62% |
| 5-year return | -58.41% | -88.35% |
| Forward P/E | 4.28 | 12.14 |
| EPS (TTM) | $-0.54 | $-1.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.00 | $20.90 |
| 52-week low | $2.10 | $11.83 |
| Distance from 52-week high | -36.25% | -43.06% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +234.12% | +5.04% |
| Average volume | 202.76K | 66.16K |
| Shares outstanding | 99.43M | 21.12M |
| Employees | 90 | 80 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About AC Immune SA
ACIU stock →AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 90 employees
About Amarin
AMRN stock →Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 80 employees
ACIU vs AMRN FAQ
Which is bigger, AC Immune SA or Amarin?
AC Immune SA (ACIU) is larger, with a market capitalization of $253.54M compared with $251.36M for Amarin (AMRN).
Which stock has performed better over the past year, ACIU or AMRN?
ACIU returned -28.41% over the past 12 months, compared with -37.62% for AMRN (price return, excluding dividends). Past performance does not predict future results.
Are AC Immune SA and Amarin in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.